Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer

The Eighth Edition <scp>AJCC</scp> Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging

Mahul B. Amin, Frederick L. Greene, Stephen B. Edge et al. · CA A Cancer Journal for Clinicians · 2017 · 6.5K citations · Full text

Medicine, Cancer Biology, Oncology +17

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

Medicine, Molecular Biology, Oncology +14

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

D. Ross Camidge, Rafał Dziadziuszko, Solange Peters et al. · Journal of Thoracic Oncology · 2019 · 491 citations · Full text

Medicine, Oncology, Pharmacology +15

Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i>-Positive Lung Cancer

Viola W. Zhu, Satoshi Yoda, Beow Y. Yeap et al. · Journal of Clinical Oncology · 2018 · 337 citations · Full text

Medicine, Oncology, Pharmacology +17